

Cost of Test

Artera will work with your insurance company to seek reimbursement for this test. If you have Medicare Fee For Service, there is an established payment rate and you should have no out-of-pocket costs.

If your out-of-pocket costs are greater than \$285, please contact Artera to learn more about available financial assistance programs.

Patients who have questions or wish not to have the test performed should contact Artera and a team member will respond to your inquiry.

How to Order

1.



Physician orders the test.

2.



Existing biopsy sample sent to our lab.

3.



Test results sent to ordering physician.

4.



Patient and physician review results together.

To learn more:

Visit artera.ai or scan the QR code



For general questions,
please contact:
info@artera.ai

For billing questions,
please contact:
billing@artera.ai
1-650-239-7018



ArteraAI Prostate Test



ArteraAI Prostate Test



Patients diagnosed with localized prostate cancer are faced with many treatment options and uncertainty about what is right for them.



Based on individual patient characteristics, the ArteraAI Prostate Test can provide insight into the following:


- Risk of developing distant metastasis
- Risk of prostate cancer-specific mortality
- Active surveillance as a suitable option^a
- Reduction in risk of distant metastasis by adding short-term androgen deprivation therapy to radiation therapy^b

The ArteraAI Prostate Test can help determine the best cancer treatment plan.

^aFor patients with NCCN very low-, low-, or favorable-intermediate risk.

^bFor patients with NCCN intermediate-risk.

How it Works



Sample Test Results

ARTERA Name: John Doe Date of Birth: 08/08/1954

ArteraAI Prostate Test Report

PATIENT DETAILS

PATIENT Name: John Doe Date of Birth: 08/08/1952 Condition: Prostate Cancer	PHYSICIAN Name: Adam Smith, MD Clinic Name: Artera Hospital	CLINICAL AND PATHOLOGY Clinical Tumor Stage: T1c Pre-biopsy PSA: 5.8 ng/mL Gleason Score: 7 (3+4) Patient Age at Order Date: 71 NCCN Risk: Favorable/Intermediate
---	--	---

ORDER
Order Date: 07/01/2023
Test Run Date: 07/04/2023
Artera ID: AM-4Y-VRD-008K

PROGNOSTIC RISK
ArteraAI Prognostic Raw Score: 0.15

10-YEAR RISK OF DISTANT METASTASIS

HIGH	INTERMEDIATE	LOW
100%	3%	1.8% RISK
10%	1%	0.8%
0%	0%	0.0%

ACTIVE SURVEILLANCE (AS) INSIGHTS
This patient's relative risk of adverse pathology at radical prostatectomy (RP) is in the 30th percentile of a cohort of patients managed with AS who had RP.

10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY
0.8% (95% CI: 0.6%-1.0%)

ST-ADT BIOMARKER
Negative
On average, patients with this result had **no clear risk reduction** in distant metastasis with the addition of short-term androgen deprivation therapy.^a

07/01/2023 12:00PM
Reviewed and Signed: Joshua B. Kish, MD
Reviewed Date and Time (EST)

The ArteraAI Prostate Test results are provided to support risk-based decisions within the recommended guidelines.
(By signing this we are confirming adequate quality of the material received, image reviewed and presence of cancer, unless otherwise noted in this report.)

Testing Laboratory: 6800 Southpoint Pkwy, Suite 950, Jacksonville, FL 32216 | CLIA ID: 1002258449 | Laboratory Director: Joshua B. Kish, MD
© 2024, ARTERA Inc. | TEL: 680 299 7018 | FAX: 680 231 6899 | EMAIL: support@artera.ai

1 Prognostic Risk

This biomarker explains the cancer's aggressiveness, presented as the risk of distant metastasis at 10 years.

2 Active Surveillance Insights

For men with lower risk^a prostate cancer, the likelihood of the patient's cancer showing more aggressive features in the future is compared to other patients managed with active surveillance.

3 Predictive Biomarker

For men with NCCN intermediate-risk cancer, this result can help determine if adding ST-ADT will be beneficial.

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Please consult with your health care provider for personalized medical advice and determine if the ArteraAI Prostate Test is appropriate for you.